Cheplapharm Arzneimittel GmbH
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cheplapharm Arzneimittel GmbH
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
With more paid prescriptions adding to Mounjaro revenue, along with increasing prescription volume, Lilly is working to increase supply of the GLP-1/GIP agonist as it awaits FDA’s call on a weight-loss indication.
The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.
Japanese major presses on with post-Shire divestments even after passing strategic target.
- Specialty Pharmaceuticals
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.